417 related articles for article (PubMed ID: 19012391)
21. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors.
Chang WP; Koelsch G; Wong S; Downs D; Da H; Weerasena V; Gordon B; Devasamudram T; Bilcer G; Ghosh AK; Tang J
J Neurochem; 2004 Jun; 89(6):1409-16. PubMed ID: 15189343
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.
Thompson LA; Liauw AY; Ramanjulu MM; Kasireddy-Polam P; Mercer SE; Maduskuie TP; Glicksman M; Roach AH; Meredith JE; Liu RQ; Combs AP; Higaki JN; Cordell B; Seiffert D; Zaczek RC; Robertson DW; Olson RE
Bioorg Med Chem Lett; 2006 May; 16(9):2357-63. PubMed ID: 16473009
[TBL] [Abstract][Full Text] [Related]
23. Purine derivatives as potent gamma-secretase modulators.
Rivkin A; Ahearn SP; Chichetti SM; Hamblett CL; Garcia Y; Martinez M; Hubbs JL; Reutershan MH; Daniels MH; Siliphaivanh P; Otte KM; Li C; Rosenau A; Surdi LM; Jung J; Hughes BL; Crispino JL; Nikov GN; Middleton RE; Moxham CM; Szewczak AA; Shah S; Moy LY; Kenific CM; Tanga F; Cruz JC; Andrade P; Angagaw MH; Shomer NH; Miller T; Munoz B; Shearman MS
Bioorg Med Chem Lett; 2010 Apr; 20(7):2279-82. PubMed ID: 20207146
[TBL] [Abstract][Full Text] [Related]
24. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
[TBL] [Abstract][Full Text] [Related]
25. Rac1 changes the substrate specificity of gamma-secretase between amyloid precursor protein and Notch1.
Boo JH; Sohn JH; Kim JE; Song H; Mook-Jung I
Biochem Biophys Res Commun; 2008 Aug; 372(4):913-7. PubMed ID: 18538664
[TBL] [Abstract][Full Text] [Related]
26. Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets.
Cole DC; Stock JR; Chopra R; Cowling R; Ellingboe JW; Fan KY; Harrison BL; Hu Y; Jacobsen S; Jennings LD; Jin G; Lohse PA; Malamas MS; Manas ES; Moore WJ; O'Donnell MM; Olland AM; Robichaud AJ; Svenson K; Wu J; Wagner E; Bard J
Bioorg Med Chem Lett; 2008 Feb; 18(3):1063-6. PubMed ID: 18162398
[TBL] [Abstract][Full Text] [Related]
27. Gamma-secretase: a complex target for Alzheimer's disease.
Lundkvist J; Näslund J
Curr Opin Pharmacol; 2007 Feb; 7(1):112-8. PubMed ID: 17169612
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands.
Ghosh AK; Kumaragurubaran N; Hong L; Kulkarni SS; Xu X; Chang W; Weerasena V; Turner R; Koelsch G; Bilcer G; Tang J
J Med Chem; 2007 May; 50(10):2399-407. PubMed ID: 17432843
[TBL] [Abstract][Full Text] [Related]
29. Tetrahydroquinoline sulfonamides as gamma-secretase inhibitors.
Asberom T; Bara TA; Clader JW; Greenlee WJ; Guzik HS; Josien HB; Li W; Parker EM; Pissarnitski DA; Song L; Zhang L; Zhao Z
Bioorg Med Chem Lett; 2007 Jan; 17(1):205-7. PubMed ID: 17046254
[TBL] [Abstract][Full Text] [Related]
30. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
31. Amino-caprolactam γ-secretase inhibitors showing potential for the treatment of Alzheimer's disease.
Neitzel ML; Aubele DL; Marugg JL; Jagodzinski JJ; Konradi AW; Pleiss MA; Szoke B; Zmolek W; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Bova MP; Hemphill S; Basi G
Bioorg Med Chem Lett; 2011 Jun; 21(12):3715-20. PubMed ID: 21571529
[TBL] [Abstract][Full Text] [Related]
32. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
[TBL] [Abstract][Full Text] [Related]
33. Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE).
Boy KM; Guernon JM; Shi J; Toyn JH; Meredith JE; Barten DM; Burton CR; Albright CF; Marcinkeviciene J; Good AC; Tebben AJ; Muckelbauer JK; Camac DM; Lentz KA; Bronson JJ; Olson RE; Macor JE; Thompson LA
Bioorg Med Chem Lett; 2011 Nov; 21(22):6916-24. PubMed ID: 21782431
[TBL] [Abstract][Full Text] [Related]
34. Advances in gamma-secretase modulation.
Pissarnitski D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
[TBL] [Abstract][Full Text] [Related]
36. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
[TBL] [Abstract][Full Text] [Related]
37. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
[TBL] [Abstract][Full Text] [Related]
38. γ-Secretase as a target for Alzheimer's disease.
Wolfe MS
Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
[TBL] [Abstract][Full Text] [Related]
39. New pyrazolyl and thienyl aminohydantoins as potent BACE1 inhibitors: exploring the S2' region.
Malamas MS; Erdei J; Gunawan I; Barnes K; Hui Y; Johnson M; Robichaud A; Zhou P; Yan Y; Solvibile W; Turner J; Fan KY; Chopra R; Bard J; Pangalos MN
Bioorg Med Chem Lett; 2011 Sep; 21(18):5164-70. PubMed ID: 21835615
[TBL] [Abstract][Full Text] [Related]
40. Nitrogen-appended N-alkylsulfonamides as inhibitors of gamma-secretase.
Bergstrom CP; Sloan CP; Wang HH; Parker MF; Smith DW; Zheng M; Hansel SB; Polson CT; Barber LE; Bursuker I; Guss VL; Corsa JA; Barten DM; Felsenstein KM; Roberts SB
Bioorg Med Chem Lett; 2008 Jan; 18(1):175-8. PubMed ID: 18023581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
